Recce Pharmaceuticals Ltd (ASX: RCE) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Recce Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $116.25 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 203.95 million
Earnings per share -0.064
Dividend per share N/A
Year To Date Return -0.93%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Recce Pharmaceuticals Ltd (ASX: RCE)
    Latest News

    hand covered in gold spray paint touching golden egg representing asx growth shares
    ⏸️ Shares to Watch

    How I'd turn $5,000 into $100,000 with ASX growth shares

    Investing in ASX growth shares can be extemely rewarding for investors prepared to hold on to them. Could my 2…

    Read more »

    digital stock graph against backdrop of world map and covid bugs
    Share Gainers

    Recce Pharmaceuticals (ASX:RCE) rockets to record high on COVID-19 update

    The Recce Pharmaceuticals Ltd (ASX:RCE) share price is rocketing higher today after revealing a positive update on its COVID-19 testing...

    Read more »

    increasing bar graph created from medical tablets
    Share Market News

    Recce share price jumps 15% on positive data

    The Recce share price jumped nearly 15% higher today on news out of the company before being sold off to…

    Read more »

    Rocket shooting out of investors outstretched hands to signify fast growth of ASX tech share
    Share Market News

    3 unloved ASX growth shares that could make you rich

    Right now, most growth investors are looking at payment, BNPL and tech stocks. However, Australia also has great science companies…

    Read more »

    Rocket launching into space
    Record Highs

    Why the Recce Pharmaceuticals share price just rocketed 31% higher to a record high

    The Recce Pharmaceuticals Ltd (ASX:RCE) share price rocketed 31% higher to a record high this morning. Here's why its shares…

    Read more »

    Share Gainers

    Why PointsBet, Recce Pharmaceuticals, Vocus, & Webjet shares are storming higher

    Recce Pharmaceuticals Ltd (ASX:RCE) and Webjet Limited (ASX:WEB) shares are two of four storming notably higher on Thursday. Here's why...

    Read more »

    ⏸️ Investing

    2 ASX shares that could be 10-baggers

    A 10-bagger share is one that returns 10 times your initial investment. Here are 2 ASX shares that I think…

    Read more »

    RCE ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Recce Pharmaceuticals Ltd

    Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs totreat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.

    RCE Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 Apr 2024 $0.57 $0.04 7.55% 506,227 $0.53 $0.58 $0.53
    19 Apr 2024 $0.53 $0.02 3.88% 646,688 $0.50 $0.55 $0.50
    18 Apr 2024 $0.52 $-0.02 -3.77% 132,721 $0.55 $0.55 $0.50
    17 Apr 2024 $0.53 $-0.02 -3.64% 113,836 $0.55 $0.57 $0.53
    16 Apr 2024 $0.55 $0.06 12.12% 175,911 $0.52 $0.55 $0.52
    15 Apr 2024 $0.50 $-0.02 -3.92% 140,938 $0.53 $0.54 $0.50
    12 Apr 2024 $0.51 $0.04 8.42% 239,629 $0.48 $0.51 $0.48
    11 Apr 2024 $0.48 $0.03 6.67% 56,724 $0.46 $0.48 $0.46
    10 Apr 2024 $0.45 $-0.02 -4.26% 48,368 $0.47 $0.48 $0.45
    09 Apr 2024 $0.47 $0.01 2.17% 76,598 $0.46 $0.48 $0.45
    08 Apr 2024 $0.46 $0.01 2.22% 133,472 $0.46 $0.46 $0.45
    05 Apr 2024 $0.45 $0.01 2.27% 36,489 $0.44 $0.45 $0.43
    04 Apr 2024 $0.44 $-0.02 -4.40% 13,906 $0.45 $0.45 $0.44
    03 Apr 2024 $0.46 $0.02 4.55% 63,257 $0.45 $0.46 $0.44
    02 Apr 2024 $0.44 $0.00 0.00% 32,869 $0.44 $0.45 $0.43
    28 Mar 2024 $0.44 $0.01 2.33% 55,731 $0.43 $0.44 $0.43
    27 Mar 2024 $0.43 $-0.01 -2.27% 7,937 $0.44 $0.44 $0.43
    26 Mar 2024 $0.44 $-0.01 -2.25% 2,275,304 $0.45 $0.45 $0.43
    25 Mar 2024 $0.45 $-0.02 -4.35% 159,945 $0.46 $0.46 $0.45

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    14 Dec 2023 Michele Dilizia Sell 836,405 $334,562
    Off-market trade.
    07 Dec 2023 John Prendergast Issued 56,819 $25,000
    Rights issue.
    07 Dec 2023 Justin Ward Issued 136,364 $60,000
    Rights issue.
    07 Dec 2023 Alan Dunton Issued 56,819 $25,000
    Rights issue.
    29 Sep 2023 James Graham Transfer 262,347 $127,238
    As advised by the company. Transfer of shares from direct holdings and
    entities controlled by Mr Graham
    29 Sep 2023 James Graham Transfer 262,347 $127,238
    As advised by the company. Transfer of shares from direct holdings and
    entities controlled by Mr Graham
    29 Sep 2023 James Graham Issued 233,430 $102,709
    Rights issue.
    29 Sep 2023 Alistair McKeough Issued 961 $422
    Rights issue.
    29 Sep 2023 Justin Ward Issued 6,114 $2,690
    Rights issue.
    22 Jun 2023 James Graham Buy 500,000 $295,000
    On-market trade. Date & Value Consideration not considered as not clear in announcement
    15 Jun 2023 James Graham Transfer 2,577,985 $1,314,772
    As advised by the company. transfer of securities between entities controlled by Mr Graham with no change to Mr Graham's relevant interest
    Date and Value consideration not considered as not clear in the announcement.
    15 Jun 2023 James Graham Transfer 2,577,985 $1,314,772
    As advised by the company. transfer of securities between entities controlled by Mr Graham with no change to Mr Graham's relevant interest
    Date and Value consideration not considered as not clear in the announcement.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr James Hamilton Bray Graham Executive DirectorChief Executive Officer Jun 2015
    Mr Graham has a background in marketing, business development and commercialisation of early-stage technology with global potential. Mr Graham continues to work with the growth and direction of Company, routinely investing alongside shareholders in capital rounds to date. He is member of Risk Management Committee.
    Mr Alistair Gregory McKeough Non-Executive Director Nov 2017
    Mr McKeough has experience in a variety of private and listed corporations across many sectors, including professional services, technology, financial services, charities, health, biotech, child care and education. He recently stepped down as Managing Director of a legal practice specialising in equity capital markets and advice to listed companies and as part of the senior leadership team at share registry, Automic Group. He is Chairman of Risk Management Committee.
    Dr Alan William Dunton Non-Executive Director Jul 2020
    Dr Dunton has held positions at biotechnology and pharmaceutical companies including serving as president and chief executive officer at Panacos Pharmaceuticals, Inc., Metaphore Pharmaceuticals, Inc., and chief operating officer at Emisphere Technologies, Inc. Dr Dunton served in several positions at Johnson and Johnson including president and managing director at the Janssen Research Foundation where he was responsible for leading over 2,000 professionals worldwide and prior to this as vice president of global clinical research and development at the R.W. Johnson Pharmaceutical Research Institute. During his career, Dr Dunton has been responsible for the approval of approximately 20 New Drug Applications; an amalgamation of prescription and OTC products. He is member of Risk Management Committee and directorships held in other listed entities during the last three years were with Palatin Technologies, Inc. (NYSE: PTN), Oragenics, Inc. (NYSE: OGEN), CorMedix, Inc. (NYSE: GRMD),Regeneus Ltd (ASX: RGS).
    Ms Michele Keryn Dilizia Executive Director Jun 2015
    Ms Dilizia had a executive career in public relations and marketing for a retail chain. Ms Dilizia was a market research consultant, which included marketing development of health-care and pharmaceutical products
    Dr John Prendergast Non-Executive DirectorNon-Executive Chairman Apr 2018
    Dr Prendergast is currently Non-Executive Chairman and Co-Founder of Palatin Technologies developing targeted therapeutics for the treatment of diseases with unmet medical need and Director of Nighthawk Biosciences, Inc., a publicly traded, clinical stage immunomodulatory company. He was previously a member of the board of the life science companies, Avigen, AVAX Technologies and MediciNova Inc and also as a member of the Advisory Board for the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree Institute. Prior to that he was a Managing Director of The Castle Group Ltd., a New York medical venture capital firm. Dr Prendergast held Post-Doctoral Fellowships in the Department of Biochemistry and Molecular Biology, Harvard University and at the Center for Research on Blood Diseases in Paris with Professor Jean Dausset (Nobel Prize, 1980). During his career, Dr Prendergast has been responsible for the approval of three New Drug Applications. He is member of risk management committee. Directorships held in other listed entities during the last three years includes Heat Biologics, Inc. (NASDAQ: HTBX).
    Dr Justin Leigh Ward Executive Director Jul 2019
    Dr Ward has specialisation in pharmaceutical quality management and product development. Before Recce Pharmaceuticals, he held a technical speciality and special project leadership role with Pfizer Pharmaceuticals, involving providing data for the regulatory submissions to the FDA and TGA. After Pfizer, he was the Laboratory Manager for Solbec, involving, again as presently, drug specifications and pharmaceutical trials for the ASX-Listed company. Most recently, he was Quality Manager at Phebra and responsible for product quality and release of all drugs of the company with the TGA.
    Ms Maggie Niewidok Company Secretary Sep 2022
    -
    Justin Reynolds Chief Financial Officer
    -
    Maggie Niewidok Company Secretary
    -
    Daniel Astudillo Head of Marketing
    -
    Thomas Jarrett Operations Manager
    -
    Arthur Kollaras Principal Engineer & Head of Manufacturing
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Graham Melrose And Olga Melrose 37,028,311 18.81%
    Hsbc Custody Nominees (Australia) Limited 13,162,919 6.69%
    M Rogers and A Veliss 7,000,000 3.56%
    Mr James Graham 6,531,932 3.32%
    Acuity Capital Investment Management Pty Ltd <Acuity Capital Holdings A/c> 4,500,000 2.29%
    Citicorp Nominees Pty Limited 3,694,057 1.88%
    Ms Michele Keryn Dilizia 3,543,485 1.80%
    Acewood Investments Pty Ltd <Chivers Super Fund A/C> 3,184,616 1.62%
    Mr John James Liddelow <John Liddelow A/C> 2,910,000 1.48%
    Pejay Pty Limited 2,500,000 1.27%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 2,487,783 1.26%
    Merrill Lynch (Australia) Nominees Pty Limited 2,449,559 1.24%
    LDU Pty Ltd 2,143,881 1.09%
    Querion Pty Ltd 2,100,000 1.07%
    Haultrans Management Pty Limited <Successful Super Fund A/C> 1,800,000 0.91%
    Bnp Paribas Noms Pty Ltd <Drp> 1,721,246 0.87%
    Mr Michael Noel Aarons & Mrs Mami Aarons <The Aarons Superfund A/C> 1,437,498 0.73%
    Mark David Swinn 1,314,720 0.67%
    Mr Nikolai Shirobokov & Mrs Svetlana Shirobokov 1,181,974 0.60%
    20 BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C> 1,095,061 0.56%

    Profile

    since

    Note